European Leukemia Trial Registry
Trial: AMLSG 15-10

More Details
Title Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation
Scientific Title Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation
Short Title AMLSG 15-10
Trialgroup AMLSG Ulm
Type of Trial multicentric, randomized, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age > 60 years
Status No longer recruiting
Start of Recruitment 01.01.2011
Leader Döhner, Prof. Dr. med., Hartmut
Contactperson

Biometrics
Benner, A.
Tel: +49 (0)6221 422390
Fax: +49 (0)6221 422397
Email: benner@dkfz-heidelber.de
Homepage: www.dkfz.de

Study Centre
Weber, Daniela
Tel: +49 (0)731 50056072
Fax: +49 (0)731 50045905
Email: aml.sekretariat@uniklinik-ulm.de

Shortprotocol Shortprotocol
Diagnostics

Molecular Genetics
Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm
Institut für Humangenetik, Medizinische Hochschule Hannover (MHH)

Testmethod
Hämatologie, Hämostaseologie, Onkologie Hannover

created 08.12.2010 Johannes Kraus
changed 21.02.2017 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org